LLY vs. VTRS: Eli Lilly vs. Viatris Stock Comparison

November 11, 2026

How do Eli Lilly (LLY) and Viatris (VTRS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Eli Lilly (LLY) and Viatris (VTRS) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.

Company profile comparison for Eli Lilly (LLY) and Viatris (VTRS)
Profile Item	LLY	VTRS
Name	Eli Lilly and Company	Viatris Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Pharmaceuticals	Pharmaceuticals
GICS Sub-Industry	Pharmaceuticals	Pharmaceuticals
Market Capitalization	1,206.07 billion USD	22.83 billion USD
Currency	USD	USD
Exchange	NYSE	Nasdaq
Listing Date	June 1, 1972	March 17, 1980
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

LLY

VTRS

GSPC

Eli Lilly (LLY) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Eli Lilly (LLY) and Viatris (VTRS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Eli Lilly (LLY) and Viatris (VTRS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
Total Return (1Y)	52.36%	108.98%
Total Return (3Y, Annualized)	34.18%	36.75%
Total Return (5Y, Annualized)	41.08%	11.59%

Risk Profile

Drawdown History

LLY

VTRS

GSPC

Eli Lilly (LLY) vs. Viatris (VTRS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Eli Lilly (LLY) and Viatris (VTRS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
Volatility (1Y, Annualized)	35.34%	32.53%
Beta (5Y)	0.40	0.86
Max Drawdown (5Y)	-34.48%	-45.69%
Avg. Volume (3M)	2.52M	8.87M

Risk-Adjusted Performance

Risk-Return Positioning

LLY and VTRS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
Sharpe Ratio (1Y)	1.36	3.22
Sortino Ratio (1Y)	2.29	5.63

Profitability

ROE (TTM)

Viatris (VTRS) reports a negative ROE of -4.21%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Eli Lilly (LLY) reports 86.02%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max: 109.18%
LLY: 86.02%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.21%

Max: 109.18%
Q3: 6.23%
VTRS: -4.21%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Viatris (VTRS) reports a negative net margin of -4.13%, usually indicating a net loss over the period. Meanwhile Eli Lilly (LLY) reports 31.90%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY: 31.90%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

-4.13%

Max: 18.05%
Q3: 4.78%
Median: 0.00%
VTRS: -4.13%
Q1: -4.14%
Min: -17.05%

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Eli Lilly (LLY) at 53.66% operates in the top operating margin quartile, ahead of Viatris (VTRS) at 13.85%, which runs around its industry’s norm.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max: 83.12%
LLY: 53.66%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.85%

Max: 83.12%
Q3: 14.77%
VTRS: 13.85%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
ROE (TTM)	86.02%	-4.21%
ROA (TTM)	21.06%	2.91%
Net Margin (TTM)	31.90%	-4.13%
Operating Margin (TTM)	53.66%	13.85%
Gross Margin (TTM)	83.63%	41.13%

Growth

Revenue Growth

Eli Lilly (LLY) at 44.70% is around its peer norm for revenue growth, while Viatris (VTRS) at -2.98% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Eli Lilly (LLY) reports EPS growth of 95.99%, ranked against its industry; Viatris (VTRS) has no EPS growth figure this period.

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
Revenue Growth (YoY)	44.70%	-2.98%
Revenue Growth (3Y CAGR)	31.69%	-4.20%
EPS Growth (YoY)	95.99%	--
EPS Growth (3Y CAGR)	51.71%	--

Financial Strength

Current Ratio (MRQ)

Both Eli Lilly (LLY) at 1.39 and Viatris (VTRS) at 1.55 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
LLY: 1.39
Min: 0.10

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
VTRS: 1.55
Min: 0.10

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Both Eli Lilly (LLY) at 1.23 and Viatris (VTRS) at 0.99 lean more heavily on debt funding than most peers, landing in the higher-leverage quartile of their industries.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max: 1.42
LLY: 1.23
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.99

Max: 1.42
VTRS: 0.99
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
Current Ratio (MRQ)	1.39	1.55
Debt / Equity (MRQ)	1.23	0.99
Net Debt / EBITDA	0.96	2.64

Dividends

Dividend Yield (TTM)

Both Eli Lilly (LLY) at 0.49% and Viatris (VTRS) at 2.53% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY: 0.49%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.53%

VTRS: 2.53%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Viatris (VTRS) reports payout ratio above 100% at 960.00%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Eli Lilly (LLY) reports 21.71%, ranking against industry peers normally.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY: 21.71%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

960.00%

VTRS: 960.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
Dividend Yield (TTM)	0.49%	2.53%
Dividend Payout Ratio (TTM)	21.71%	960.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: Eli Lilly (LLY) trades at 43.95 times trailing earnings, ranked against its peers, while Viatris (VTRS) has no P/E ratio this period.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max: 85.34
LLY: 43.95
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 85.34
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07
VTRS: --

Eli Lilly (LLY) vs. Viatris (VTRS): VTRS does not report P/E ratio, so it has no value marker; LLY is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

Viatris (VTRS) at 1.55 sits in the cheaper P/S ratio quartile while Eli Lilly (LLY) at 13.95 prices around its industry’s middle — VTRS costs less per dollar of sales, though read it alongside growth and margins.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max: 58.18
Q3: 25.77
LLY: 13.95
Median: 7.30
Q1: 3.01
Min: 0.01

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.55

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
VTRS: 1.55
Min: 0.01

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Viatris (VTRS) at 1.67 sits in the lower P/B ratio quartile relative to book while Eli Lilly (LLY) at 29.96 prices above its industry range — a wide valuation gap against assets.

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY: 29.96
Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

VTRS

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
VTRS: 1.67
Min: -5.59

Eli Lilly (LLY) vs. Viatris (VTRS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Eli Lilly (LLY) and Viatris (VTRS)
Metric	LLY	VTRS
P/E Ratio (TTM)	43.95	--
P/S Ratio (TTM)	13.95	1.55
P/B Ratio (MRQ)	29.96	1.67
Free Cash Flow Yield (TTM)	0.77%	13.84%